RA Session

Dallas’ Taysha Gene Therapies Gets Worldwide Rights to Gene Therapy That Treats a Rare Neurodegenerative Disease

by | Apr 12, 2021
Taysha Gene Therapies, which rocketed from a UTSW spinout to a $157 million IPO in under six months last year, has gone global with rights to TSHA-120, a promising AAV9 clinical-stage gene therapy.

It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer. 
MORE►
Success in the Genes: Launching in a Pandemic Didn’t Hurt This Fast-Growth Dallas Biotech Company
by | Feb 26, 2021
In under six months, Taysha Gene Therapies rocketed from the unveiling of its UTSW spinout to a $157 million initial public offering. We talk with Founder and CEO R.A. Session II about the biotech with big plans.
MORE►
Taysha and UTSW Launch Innovation Fund to Advance the Development of New Gene Therapies
by | Jan 13, 2021
The expanded alliance between Taysha and UTSW, which dates back to when Taysha emerged from stealth in April 2020, will support the discovery of novel gene therapy candidates and technologies in new disease areas.
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2024 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners